Search Results
Your search for it matches 16118 pages
Showing 3601 - 3650Study Identifies Factors Impacting Adherence to Oral Medications for Metastatic Breast Cancer
A recent study published by Conley et al in Breast Cancer Research and Treatment aimed to evaluate factors that influence the ability of people with metastatic breast cancer to adhere to their prescribed regimen of oral anticancer medication. Researchers found that multiple factors affected...
Study Finds Patients With Lung Cancer Demonstrated Psychological Resilience in the Face of the COVID-19 Pandemic
Far from being hobbled by fears of COVID-19, patients with lung cancer actually showed less depression and anxiety during the pandemic than their healthy peers, according to results from a new study by Arrato et al published in JNCCN–Journal of the National Comprehensive Cancer Network. Researchers ...
Guideline Update Highlights the Importance of Shared Decision-Making Regarding the Use of Adjuvant Therapy in Stage II Colon Cancer
ASCO has published updated guidance on the use of adjuvant therapy in the management of stage II colon cancer, providing clinicians with a newer evidence-based framework that can be used in shared decision-making with patients.1 Need for Updated Guidance “How to approach patients with stage II...
Use of Consolidation Durvalumab and Adjuvant Osimertinib Among Key Recommendations in New ASCO Guideline on Stage III NSCLC Treatment
A new ASCO guideline provides key recommendations for the evaluation and management of stage III non–small cell lung cancer (NSCLC). Recommendations made by the ASCO expert panel cover evaluation and staging of NSCLC, neoadjuvant and adjuvant therapies, and the management of unresectable ...
How to Rein in Oncology Costs and Save Physician-Owned Practices
I was honored to contribute a chapter on the cancer care delivery system and how to improve it for the book A New Deal for Cancer: Lessons From a 50 Year War, edited by Abbe R. Gluck and Charles Fuchs, MD, MPH (Public Affairs, 2021). The book chronicles what has been accomplished in the 50 years...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in the Russian Federation
The Russian Federation is the largest country in the world, extending from Eastern Europe to Northern Asia and the Pacific Ocean. The population of more than 140 million people is unevenly distributed across the country.1 As a result, Russia has high spatial inequality in terms of accessibility of...
RxPONDER Trial: Another Step in Defining Which Patients With Breast Cancer May Be Spared Adjuvant Cytotoxic Chemotherapy
As reported by Kalinsky et al and summarized in this issue of The ASCO Post, an interim analysis of the phase III RxPONDER trial showed that the addition of adjuvant chemotherapy to endocrine therapy improved invasive disease–free survival among premenopausal—but not postmenopausal—women with...
Expert Point of View: Charles Shapiro, MD
Charles Shapiro, MD, Professor of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, commented on the study findings. “MA.32 is a large, randomized placebo-controlled trial of metformin in over 3,600 women with invasive breast cancer. The rationale for...
Metformin Added to Standard Adjuvant Chemotherapy Fails to Improve Outcomes in Early Breast Cancer
The addition of metformin, a drug commonly used to treat type 2 diabetes, to standard adjuvant treatment failed to improve invasive disease–free survival or overall survival for hormone receptor–positive or –negative breast cancer, according to the results of a large landmark trial led by the...
Jane N. Winter, MD, Begins Term as 2022 ASH President
Jane N. Winter, MD, a highly regarded lymphoma expert, will serve as President of the American Society of Hematology (ASH) for a year-long term through December 2022. Dr. Winter is Professor of Medicine in the Division of Hematology/Oncology, a member of the Robert H. Lurie Comprehensive Cancer...
Jaye Gardiner, PhD, Receives Inaugural Black in Cancer Postdoctoral Fellowship for Pancreatic Cancer Research
Jaye Gardiner, PhD, a postdoctoral researcher at Fox Chase Cancer Center, has received an inaugural Black in Cancer postdoctoral fellowship, which is funded by Emerald Foundation Inc. Dr. Gardiner will receive $75,000 annually for 3 years, which will fund her research into pancreatic ductal...
Expert Point of View: Angela DeMichele, MD, MSCE
Angela DeMichele, MD, MSCE, the Alan and Jill Miller Professor in Breast Cancer Excellence at the Perelman School of Medicine of the University of Pennsylvania in Philadelphia, commented on NIMBUS1 for The ASCO Post. She said obtaining information on tumor mutational burden is simple, as it is part ...
Expert Point of View: Debu Tripathy, MD, and Hope S. Rugo, MD, FASCO
The ASCO Post asked Debu Tripathy, MD, Professor and Chair of Medical Breast Oncology at The University of Texas MD Anderson Cancer Center, Houston, and Hope S. Rugo, MD, FASCO, Professor of Medicine, Director of Breast Oncology and Clinical Trials Education at the University of California San...
After Two Cancer Diagnoses, I’m Grateful for Another Day
The start of January 2014 was filled with excitement. I was undergoing fertility treatments to have a second child and was living my professional dream. I was a network news anchor and medical news reporter for a national broadcast network. Although I was exhausted from my grueling early morning...
Datopotamab Deruxtecan Shows Activity in Advanced Triple-Negative Breast Cancer
Datopotamab deruxtecan, an antibody-drug conjugate directed against trophoblast cell surface antigen-2 (Trop-2), is showing promise as a treatment for relapsed or refractory advanced triple-negative breast cancer, according to early findings from the phase I TROPION-PanTumor01 trial presented...
Expert Point of View: Anne Blaes, MD
Invited discussant Anne Blaes, MD, of the University of Minnesota, Minneapolis, emphasized the main takeaway finding of the combined updated analysis of the SOFT and TEXT trials. “In early-stage estrogen receptor–positive breast cancer, premenopausal women who don’t require chemotherapy do very...
Mindfulness in Pediatric and Adolescent Patients With Cancer
Guest Editor’s Note: Mindfulness has gained immense popularity in recent years. Growing evidence suggests the benefits of mindfulness-based practices, which include concentration meditation and guided imagery, for managing symptoms associated with cancer and its treatments. In this article,...
Evidence Supports Ovarian Function Suppression Plus Aromatase Inhibitor in Premenopausal Women With Early Breast Cancer
The benefits of ovarian function suppression were sustained long term for premenopausal women with hormone receptor–positive breast cancer, according to updates from SOFT and TEXT, two randomized, controlled trials, presented at the 2021 San Antonio Breast Cancer Symposium.1 A separate large...
Expert Point of View: Hope S. Rugo, MD, FASCO
The discussant of KEYNOTE-522 at the 2021 San Antonio Breast Cancer Symposium, Hope S. Rugo, MD, FASCO, Professor of Medicine and Director of Breast Oncology and Clinical Trials Education at the University of California San Francisco Comprehensive Cancer Center, commented: “We are clearly making...
Abatacept for Prophylaxis of Acute Graft-vs-Host Disease
On December 15, 2021, abatacept, a selective T-cell costimulation modulator, was approved for prophylaxis of acute graft-vs-host disease in combination with a calcineurin inhibitor (eg, cyclosporine, tacrolimus) and methotrexate in adults and pediatric patients aged ≥ 2 years undergoing...
Expert Point of View: Joshua Brody, MD
Joshua Brody, MD, Director of the CLL/Lymphoma Immunotherapy Program, Icahn School of Medicine at Mount Sinai, New York, who was not involved in these trials, commented: “CLL is an extremely prevalent disease affecting nearly 200,000 patients in the United States. Most patient do not require...
Fixed-Duration Venetoclax Plus Ibrutinib Achieves Deep and Durable MRD Remissions in CLL
Two different trials presented at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition found that fixed-duration treatment with ibrutinib and venetoclax achieved deep and sustained undetectable measurable residual disease (MRD) status when used as first-line therapy for...
Expert Point of View: Anthony El-Khoueiry, MD
Anthony El-Khoueiry, MD, Member of the Section of Gastrointestinal Cancers, Director of the phase I program, and Associate Professor of Clinical Medicine at the Keck School of Medicine of the University of Southern California and USC Norris Comprehensive Cancer Center, said the findings of the...
HIMALAYA Trial: First-Line Tremelimumab Plus Durvalumab Improves Overall Survival in Unresectable Hepatocellular Carcinoma
Patients with advanced, unresectable hepatocellular carcinoma may be gaining another first-line treatment option. In the global phase III HIMALAYA trial, a single priming dose of tremelimumab plus regular-interval durvalumab significantly improved overall survival, according to Ghassan K....
Expert Point of View: Nilofer Azad, MD
Nilofer Azad, MD, Professor of Oncology at Johns Hopkins University School of Medicine and Co-Director of Cancer Genetics and Epigenetics at the Sidney Kimmel Comprehensive Cancer Center, Baltimore, was invited to discuss the results of the phase III TOPAZ-1 study, which found an overall survival...
TOPAZ-1: Overall Survival Prolonged With First-Line Immunotherapy Plus Chemotherapy in Biliary Tract Cancer
For the first time, a phase III study has shown an overall survival benefit for upfront treatment using immunotherapy plus chemotherapy in advanced biliary tract cancer. In the TOPAZ-1 trial, the addition of the anti–PD-L1 agent durvalumab to gemcitabine plus cisplatin significantly improved...
City of Hope Completes Strategic Acquisition of Cancer Treatment Centers of America
On February 2, 2022, City of Hope announced that it has completed its previously announced acquisition of Cancer Treatment Centers of America (CTCA), a network of oncology hospitals and outpatient care centers across the United States. City of Hope, in Duarte, California, now has expanded its...
Oncology Drugs With Accelerated Approval: Is It Time for a Reset?
Regulations that are developed by the U.S. Food and Drug Administration (FDA) must have some shelf-life before revisions are considered. The FDA has several mechanisms to provide patients with more rapid access to medicines. One such pathway is accelerated approval. Backward Glance at Accelerated...
PALLAS Trial in Hormone Receptor–Positive, HER2-Negative Breast Cancer: Defining the Role of Adjuvant CDK4/6 Inhibition
Over the past 7 years, the introduction of combined endocrine therapy with cyclin-dependent kinase (CDK) 4/6 inhibitors resulted in a dramatic improvement in outcomes for patients with metastatic, hormone receptor–positive, HER2-negative breast cancer. Early attempts to modulate the cell cycle with ...
In All Candor, What Does CANDOR Bring to the Table in Relapsed or Refractory Multiple Myeloma?
An updated analysis of the phase III CANDOR study—recently reported by Usmani et al and summarized in this issue of The ASCO Post—confirmed a significant progression-free survival benefit for the combination of daratumumab, carfilzomib, and dexamethasone (KdD) over carfilzomib and dexamethasone...
AACR Releases Report on the Impact of COVID-19 on Cancer Research and Patient Care
On February 9, the American Association for Cancer Research (AACR) released the AACR Report on the Impact of COVID-19 on Cancer Research and Patient Care. According to findings contained within the report, patients with cancer are not only at an increased risk for developing severe COVID-19, but...
Role of CECR2 Gene in Advanced Triple-Negative Breast Cancer
A new study published by Zhang et al in Science Translational Medicine shows inhibition of the CECR2 gene may prevent triple-negative breast cancer from advancing or metastasizing. The discovery is an early step in finding new therapeutics for triple-negative breast cancer, one of the most...
Study Provides Insights Into the Genomic Basis of Cancer Metastasis
New findings from researchers at Memorial Sloan Kettering Cancer Center published by Nguyen et al in Cell support an emerging framework in cancer science that views metastasis as not primarily driven by genetic mutations, but rather, by epigenetic changes that occur in cancer cells because of their ...
Expert Point of View: Rona Yaeger, MD
Rona Yaeger, MD, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, New York, offered her thoughts on the findings of Morris et al for the combination regimen of encorafenib, cetuximab, and nivolumab in patients with microsatellite-stable BRAF V600E–mutated metastatic...
Expert Point of View: Demetris Papamichael, MB, BS
The invited discussant of the SOLSTICE trial1 was Demetris Papamichael, MB, BS, Consultant Medical Oncologist at the Bank of Cyprus Oncology Centre and Associate Professor at St. George’s Hospital and Medical School, University of London. He said that although the study concluded...
SOLSTICE Trial: Trifluridine/Tipiracil Plus Bevacizumab in Metastatic Colorectal Cancer
For the treatment of metastatic colorectal cancer in patients unfit for intensive chemotherapy, trifluridine/tipiracil plus bevacizumab as first-line therapy was no more effective than capecitabine plus bevacizumab, investigators from the phase III SOLSTICE trial reported in a European Society for...
FDA Investigating Possible Increased Risk of Death With Lymphoma Treatment Umbralisib
The U.S. Food and Drug Administration (FDA) is investigating a possible increased risk of death associated with umbralisib (Ukoniq), a kinase inhibitor including PI3K-delta and CK1-epsilon, approved to treat marginal zone and follicular lymphomas. The FDA determined that initial findings from the...
Expert Point of View: Mandana Kamgar, MD, MPH
The ASCO Post invited Mandana Kamgar, MD, MPH, Assistant Professor of Medicine at the Medical College of Wisconsin, LaBahn Pancreatic Cancer Program, Milwaukee, to comment on the KRYSTAL-1 trial. “The KRYSTAL-1 study in totality is a multiphase and multiarm ongoing study exploring the role of...
CancerCare Offers Patients Financial Assistance for Transportation, Pet Care
Financial assistance may be available for some individuals with cancer from CancerCare, a nonprofit organization helping people cope with and manage the emotional and practical challenges of cancer. Two assistance programs tailored to specific individuals are available to meet financial challenges...
Risk-Standardized Mortality Rates as Quality Proxy for Surgical Oncology
In a German study reported in the Journal of Clinical Oncology, Baum et al found that risk-standardized mortality rates may be a better-quality proxy for complex oncologic surgeries than hospital volume. As stated by the investigators, “Despite a long-known association between annual hospital...
ASCO Statement on World Cancer Day
Julie Gralow, MD, FACP, FASCO, ASCO’S Chief Medical Officer, issued the following statement in light of World Cancer Day on February 4. “This year’s World Cancer Day theme, ‘Close the Care Gap,’ speaks to the heart of what it means to achieve progress against cancer today. In the shadow of COVID’s ...
Study Examines Role of Hyaluronic Acid in Pancreatic Cancer Growth
Hyaluronic acid is a known presence in pancreatic tumors, but a new study published by Kim et al in eLife has shown that hyaluronic acid can also act as a nutrient to fuel pancreatic cancer metabolism. These findings provide insight into how pancreatic cancer cells grow and indicate new...
Can Weight Loss in Adulthood Reduce the Risk of Developing Colorectal Adenomas?
Weight loss for adults, particularly those who are overweight or obese, may reduce their risk of developing a type of polyp that may lead to colorectal cancer, according to a new study published by He et al in JNCI Cancer Spectrum. Losing weight from early to late adulthood (up to the mid-70s)—at...
Study Finds Pediatric-Based Treatment Regimen Feasible and Effective in Older Adults With ALL
A pediatric-based protocol has delivered promising preliminary results in adults with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL), according to data presented at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Findings from the large,...
Kerryn Reding, PhD, MPH, RN, Daughter of Health-Care Workers, Chooses a Career in Breast Cancer Survivorship
Kerryn Reding, PhD, MPH, RN—whose research focuses on reducing cancer incidence and improving survival, with particular interests in lifestyle interventions and biomarkers of risk—was born in Australia, but her family moved to Iowa when she was a toddler. “Both of my parents were in health care. My ...
President Biden Reignites Cancer Moonshot
As Vice President, in 2016, Joe Biden launched the Cancer Moonshot with the mission to accelerate the rate of progress against cancer. The cancer and patient community and medical researchers responded with energy and ingenuity. On February 2, President Biden announced the reigniting of the Cancer ...
ASCO and American Cancer Society Announce Collaboration to Empower People With Cancer Information They Can Trust
ASCO and the American Cancer Society (ACS) today initiated a collaboration to ensure that people can easily find the trusted, expert-approved cancer content they need when turning to either organization for information. As an initial step, the organizations are cross-sharing select cancer...
Challenges for Oncologists as They Reach Retirement Age
In 2014, The ASCO Post spoke with Mark J. Clemons, MB BS, BMedSci, MSc, MD, FRCP, FRCPC, of Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada, about the retirement challenges faced by many oncologists. With market demand expected to exceed supply of oncologists soon, it is clear retirement is...
FDA Approves New Label Update for CAR T-Cell Therapy Axicabtagene Ciloleucel
On January 31, the FDA approved an update to the prescribing information for axicabtagene ciloleucel (Yescarta) to include use of prophylactic corticosteroids across all approved indications. Axicabtagene ciloleucel is now the first and only chimeric antigen receptor (CAR) T-cell therapy with...
Study Examines Head and Neck Cancer Incidence in Black Populations Around the World
Researchers have found that disparities in the incidence of head and neck cancer are driven by behavioral and environmental risk factors rather than race. They demonstrated this in the first-ever study to compare head and neck cancer incidence in Black patients in the United States, the Caribbean,...
